Search results
GSK Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 5 hours agoWe expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales
Zacks via Yahoo Finance· 2 years agoGlaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with...
These Inhalers No Longer Cost More Than $35 Per Month
Verywell Health via Yahoo News· 1 month agoGrace Cary / Getty Images Fact checked by Nick Blackmer Key Takeaways Three major pharmaceutical...
Glaxo (GSK) Up 3.1% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo Finance· 2 months agoIt has been about a month since the last earnings report for GSK (GSK). Shares have added about 3.1%...
GSK Beats on Q1 Earnings, Lags Sales, Reaffirms 2023 Outlook
Zacks via Yahoo Finance· 12 months agoThough GSK's revenues benefit from strong growth across all segments, the declining COVID-19...
Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva
Zacks via Yahoo Finance· 2 years agoEntasis Therapeutics Holdings Inc. ETTX announced that it has signed a definitive merger agreement...
Why Is Glaxo (GSK) Up 6.7% Since Last Earnings Report?
Zacks via Yahoo Finance· 1 year agoA month has gone by since the last earnings report for GSK (GSK). Shares have added about 6.7% in...
Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results
GuruFocus.com via Yahoo Finance· 2 months agoRevenue: Innoviva Inc (NASDAQ:INVA) reported a 35% year-over-year increase in net product revenues...
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
Zacks via Yahoo Finance· 1 month agoGSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month...
Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests
Zacks via Yahoo Finance· 2 years agoTheravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The...